Haematologica

Haematologica www.haematologica.org publishes novel findings in basic, clinical and translational hematology research. Impact Factor (JCR) 7.116 (7th of 76)

Haematologica/The Hematology Journal (pISSN: 0390-6078, eISSN: 1592-8721, NLM ID: 0417435) publishes peer-reviewed papers across all areas of experimental and clinical hematology. The journal is owned by a non-profit organization, the Ferrata Storti Foundation, and serves the scientific community strictly following the International Committee of Medical Journal Editors (ICMJE, www.icmje.org) recom

mendations on publication ethics policies for medical journals. Haematologica was founded in 1920 by Adolfo Ferrata

Is age really the best guide to treating older patients with lymphoma?Older patients with lymphoma are a highly heteroge...
03/09/2026

Is age really the best guide to treating older patients with lymphoma?
Older patients with lymphoma are a highly heterogeneous population, yet arbitrary age cut-offs continue to influence treatment decisions and clinical trial eligibility.
In this review, the authors challenge age-based approaches and discuss how geriatric assessment, biological age, patient preferences, and more inclusive trial designs could help reshape treatment decisions for older patients.
https://haematologica.org/article/view/13094

Can newborn screening change the course of ataxia-telangiectasia?Newborn screening for severe combined immunodeficiency ...
30/08/2026

Can newborn screening change the course of ataxia-telangiectasia?
Newborn screening for severe combined immunodeficiency is increasingly identifying other inborn errors of immunity, raising new diagnostic and therapeutic questions.
In this Case Report, Ricci et al. describe the early detection of ataxia-telangiectasia through neonatal screening and discuss how a prompt genetic diagnosis may influence clinical management and treatment decisions.
Read more in Haematologica.
https://haematologica.org/article/view/13457

Can glofitamab trigger immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome?As the use of bi...
28/08/2026

Can glofitamab trigger immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome?
As the use of bispecific antibodies expands, recognizing rare but life-threatening immune toxicities is becoming increasingly important.
In this Case Report, Fresa et al. describe the first reported case of immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome following treatment with the CD20×CD3 bispecific antibody glofitamab, highlighting key diagnostic and management challenges.
Read more in Haematologica.
https://haematologica.org/article/view/14122

Could basophilic meningitis be the first sign of chronic myeloid leukemia?Basophilic meningitis is exceptionally rare an...
26/08/2026

Could basophilic meningitis be the first sign of chronic myeloid leukemia?
Basophilic meningitis is exceptionally rare and has almost exclusively been reported in advanced hematologic disease.
In this Case Report, Rahmé et al. describe an unusual presentation in which basophilic meningitis led to the diagnosis of chronic-phase chronic myeloid leukemia, highlighting important diagnostic and therapeutic challenges.
Read more in Haematologica.
https://haematologica.org/article/view/14119

Is it time to rethink risk stratification in polycythemia vera?Patients with polycythemia vera classified as "low risk" ...
24/08/2026

Is it time to rethink risk stratification in polycythemia vera?
Patients with polycythemia vera classified as "low risk" may still lose years of life despite current treatment strategies.
In this Perspective, the authors argue that disease biology – not age alone – should guide therapeutic decisions, discussing how biological markers could help to identify patients who may benefit from earlier intervention to prevent thrombosis and disease progression.
Read the full Perspective in Haematologica.
https://haematologica.org/article/view/13144

The translocation t(11;14) is the most clinically relevant targetable cytogenetic abnormality in multiple myeloma, shapi...
22/08/2026

The translocation t(11;14) is the most clinically relevant targetable cytogenetic abnormality in multiple myeloma, shaping response to BCL2 inhibition and opening new opportunities for biomarker-driven treatment.
In a new Review, the authors discuss the biology and prognostic significance of t(11;14), the rationale for targeting BCL2, current clinical evidence, mechanisms of resistance, and future therapeutic strategies.
Read the full Review in Haematologica.
https://haematologica.org/article/view/13074

Can bleomycin be safely omitted from the treatment of limited-stage Hodgkin lymphoma?For patients with limited-stage cla...
20/08/2026

Can bleomycin be safely omitted from the treatment of limited-stage Hodgkin lymphoma?
For patients with limited-stage classical Hodgkin lymphoma and a negative positron emission tomography (PET) scan after two cycles of ABVD, reducing treatment toxicity without compromising cure remains a key goal.
Yang et al. evaluate a PET-adapted approach that omits bleomycin after cycle 2, exploring its impact on clinical outcomes and treatment-related pulmonary toxicity.
Read more in Haematologica.
https://haematologica.org/article/view/13373

What does lymphocytosis after BCMA chimeric antigen receptor (CAR) T-cell therapy really represent?Transient lymphocytos...
18/08/2026

What does lymphocytosis after BCMA chimeric antigen receptor (CAR) T-cell therapy really represent?
Transient lymphocytosis is commonly observed after BCMA-directed CAR T-cell therapy in relapsed/refractory multiple myeloma, but its interpretation can be challenging in routine practice.
Chai et al. characterize the morphological and immunophenotypic features of post-infusion lymphocytosis and explore how CAR T-cell expansion kinetics may relate to treatment response and neurotoxicity.
Read the full Letter in Haematologica.
https://haematologica.org/article/view/13127

Evidence supporting CD19-directed chimeric antigen receptor (CAR) T-cell therapy in intravascular large B-cell lymphoma ...
16/08/2026

Evidence supporting CD19-directed chimeric antigen receptor (CAR) T-cell therapy in intravascular large B-cell lymphoma (IVLBCL) remains extremely limited, leaving important questions about its efficacy and safety unanswered.
Using real-world data from the CIBMTR registry, Patel et al. explore the outcomes of patients with relapsed or refractory IVLBCL treated with CAR T cells, providing new insights into this rare and challenging disease.
Read the full Letter in Haematologica.
https://haematologica.org/article/view/12984

Indirizzo

Via Giuseppe Belli 4
Pavia
27100

Orario di apertura

Lunedì 09:00 - 18:00
Martedì 09:00 - 18:00
Mercoledì 09:00 - 18:00
Giovedì 09:00 - 18:00
Venerdì 09:00 - 18:00

Telefono

+39038227129

Sito Web

Notifiche

Lasciando la tua email puoi essere il primo a sapere quando Haematologica pubblica notizie e promozioni. Il tuo indirizzo email non verrà utilizzato per nessun altro scopo e potrai annullare l'iscrizione in qualsiasi momento.

Contatta Lo Studio

Invia un messaggio a Haematologica:

Scelte rapide

In evidenza

Condividi